Retired
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why was the CW-WDM MSA formed?
IEEE and MSA standards specify single and four wavelengths for today’s datacom optics. Emerging Silicon Photonics (SiPh) based optics are expected to move to 8, 16, and 32 wavelengths, to support high data rate advanced optical communication and computing applications. These higher wavelength counts are a crucial part of the emerging ecosystem and will enable improvements in performance, efficiency, cost, and bandwidth scaling.
What is the goal of the CW-WDM MSA?
The goal of the MSA is to generate a set of specifications for optical power sources. Once the standard is adopted broadly, vendors can leverage a robust supply chain and suppliers have a unified, large market to sell into.
Where can I find the specification?
Download ?
How is the CW-WDM MSA different from previous standards?
The CW-WDM MSA is different from optical communication standards in that it solely focuses on defining the optical source specifications instead of the full communication link. While it has a number of end use cases, it is not targeted at any single application. Such an approach allows developers to fully optimize links without interoperability constraints, while simultaneously creating a large business opportunity for optical source suppliers.
Is there any overlap between the CW-WDM MSA and previous ethernet standards?
The MSA will leverage optical specifications in previous standards, including IEEE 100GBASE-LR4 and ITU-T DWDM G.694.1, to minimize the development effort required by suppliers and reduce product time-to-market.
What is the difference between a Promoter Member and an Observer Member?
Promoter Members develop the specifications, contribute and license IP, vote on the Standard, and actively promote the MSA. Observer Members are informed of the specification development details on an ongoing basis, and can contribute to the specifications through Promoter Members.
Poet Technologies a Next Gen Tech Company ....
Don't worry ... one morning in the future you might wake up and find you won a CASINO ... ;)
Read through the whole article ...https://setenews.com/2022/03/31/how-did-the-poet-technologies-stock-react-in-the-pre-market-session/
so true ... it must really suck to be short ... ;)
We are at least getting mentioned with some of the big boys:
Competitive Landscape
The Global Photonic Integrated Circuit Market is moderately competitive and consists of several major players like Neophotonics corporation, Poet Technologies, Cisco Systems Inc., Infinera Corporation, etc. In terms of market share, few of the major players currently dominate the market. However, with innovations and technological advancements, many of the companies are increasing their market presence by securing new contracts and by tapping new markets. Some of the recent developments in the market are:
March 2022 - EFFECT Photonics and Jabil Photonics have announced that they would collaborate on the development of a new generation of coherent optical modules. The modules offer a unique solution for network operators and hyperscalers who seek to benefit from QSFP-high DD’s performance, small footprint, low power consumption and cost, field replaceability, and vendor interoperability for cloud DCIs (Data Center Interconnects). The next-generation coherent optical modules handle the increased demand for data flow, service continuity, security issues, worldwide expansion, and sustainability.
March 2022 - ColorChip Group and Skorpios Technologies, Inc., a vertically integrated pioneer in heterogeneously integrated silicon photonics, established a strategic partnership to use Skorpios’ disruptive optical technology to produce optical modules at previously unheard-of prices. ColorChip will sell its own brand of modules as well as private label modules for Skorpios to sell at various speeds and performance levels. Future products, such as Co-packaged Optics and Coherent Modules, will be developed in collaboration.
September 2021 - NeoPhotonics announced the launch of the high output power version of its 400G Multi-Rate CFP2-DCO coherent pluggable transceiver with 0 dBm output power and designed to operate in the metro, regional, and long-haul ROADM based optical networks. It is based on NeoPhotonics vertically integrated Indium Phosphide technology platform, including the ultra-pure Nano tunable laser and Class 40 Coherent Driver Modulator (CDM) and Coherent Receiver (ICR).
https://www.reportlinker.com/p06187410/Global-Photonic-Integrated-Circuit-Market-Growth-Trends-COVID-19-Impact-and-Forecasts.html
Still looking myself, but have not found anything yet.
That's about 4 trading days total so far so I love it !!!
164,000 shares now !
THE GOOD LORD is watching out for you F2 ... GET BETTER SOON ... ;)
F2 ... stay safe ... get well ... and may GOD BLESS YOU and watch over you.
I added 1,150 shares today at an average of 7.17 ... I think we will all be very happy with our investment in POET ... ;)
We are going to have alot of movement in this stock as POET becomes better known on the NASDAQ. If you want to accummulate shares in a company with the tech that POET develops you do not want to overpay, especially if you are looking to acquire larger quantity's. We usually trade less than 100,000 shares @ trading day and normally less than 40,000 @ session.
Also, POET got alot of notice at the OFC in early March so the interest is there, but if you want to accummulate, funds and bigger players will do their best to suppress the price along the way, so don't read to much into the daily flucuations ... jmho ... ;)
Looking back since June of last year I have sent myself 65 e-mails where I copied post from this board so I could keep them in an e-mail folder and refer back to them.
This is my way of being able to quickly refer back to LWLG posts with info and knownledge about so many informative facts about LWLG. This would never be possible without this IHUB LWLG board and the wonderful longtime posters and for this, I am truly grateful to you all.
There are hundreds more of post that I have not copied yet, but I am only 70 and believe I still have some time to get around to doing so.... ;)
THANK YOU ALL,
JohnSamuel
Robert, the good news is they are still a part of the float and they are not available to trade ... ;)
THANKS Slim Jim ... the magical word ... "new" ... ;)
You and me both ... although the paramedics might have to revive me ...;)
LOL ... that a "winking eye and a smile " ... ;)
... ;)
Shorting any stock, in my opinion, is just plain stupid. Some people think that buying
"puts" is the same thing ... put simply ... IT AIN'T.
When you buy "puts" the most you can lose is your original investment, just like buying "calls" that expire worthless.
Short selling is a dumbass strategy with the very real possibility of suffering unlimited losses. The share price can only fall to "0" but there is no limit to how much the stock can go up. Just imagine the "dumbass" that sells short a 1,000 shares of LWLG at 10 @ share. He wakes up one morning in the future and his broker, E.F. MUTTON is on the phone and says, "Hey DUMBASS, LWLG was just bought out for ... wait for it ... $150 @ share so that $10 short sell for the $10,000 you put up and the additional 50% or $5,000 in your margin account ain't gonna cover your $150,000.00 LOSS."
The moral of this story is ... if you short sell LWLG ... you qualify being classified as a "DUMBASS".
RECELL® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
PDF Version
VALENCIA, Calif. and MELBOURNE, Australia, March 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium. The conference is being held in Boston and will highlight research and knowledge of both up and coming vitiligo researchers and those who have and continue to build the foundational knowledge about vitiligo.
“We are pleased to share our clinical study protocol, which aims to establish safety and effectiveness for repigmentation of stable vitiligo lesions utilizing the RECELL System, with leaders of the vitiligo community,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “With enrollment of our vitiligo pivotal trial complete, we look forward to sharing results of our blinded, randomized study in the near future and working with the FDA to bring our novel treatment option to patients.”
RECELL System Abstract
March 24 at 9:38am, Abstract #4: RECELL Autologous Cell Harvesting Device: A Review of the Science of Autologous Skin Cell Suspension and Clinical Protocol Aimed in Establishing Safety and Effectiveness for Repigmentation of Stable Vitiligo Lesions. Authors: K. Bush, A. Hopkin, E. Kirshner, A. Quick
Vitiligo is a disease that attacks pigment-producing cells, called melanocytes, resulting in their destruction or malfunction. The result is a loss of pigmentation in patches of skin. Vitiligo affects up to 2% of the population worldwide,i including an estimated 3-6.5 million Americans.ii Vitiligo has a comparable market size and psychosocial impact to other major dermatology diseases including psoriasis (thick, scaly skin) and atopic dermatitis (red, cracked skin).iiiivv Like these diseases, those living with vitiligo may suffer from poor body image along with low self-esteem, leading to an impaired quality of life.
ABOUT AVITA MEDICAL, INC.
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018 and a new ease-of-use design was approved in 2022. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.
You are so right frobinso ... he is our "Ambassador of Light" spreading the news of how they will change the industry with Perkinamine™.
It still has the same affect. It takes shares out of the general pool of available shares for sell and into the hands of Institutional investors and Funds that are now, not for sell. Also, as more buy in it takes those shares out of the trading pool and into secured hands. This is just the start of accummulation by Institutions and Funds. This would not be possible if LWLG had not uplisted to NASDAQ when they did. This is positive accummulation lessoning the pool of available shares in the marketplace.
jmho
You are correct ... the Mutual Fund is ownable by public participation whereas the Institutional ownership is owned by Vanguard itself.
jmho
Funds will support completion of the ongoing pivotal clinical trial
VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BARDA) has modified its existing contract with the Company to support AVITA Medical’s clinical trial in soft tissue reconstruction. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
“We are extremely pleased that BARDA is supporting advanced treatment options for soft tissue reconstruction,” said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. “The RECELL System has already proven itself as a safe and effective tool for those with burns, and we are committed to expanding its use to include all acute wounds. We are pleased BARDA recognizes the potential it holds for a broader group of patients experiencing trauma. BARDA has been an outstanding partner, and we are excited to continue our work to expand the indication for the RECELL System with their support.”
Soft tissue reconstruction is of particular concern to BARDA and AVITA Medical, as skin grafting, the current standard of care for soft tissue reconstruction, requires the harvesting of donor skin which can result in an additional wound to the patient. Significant pain, delayed healing, risk of infection, the need for multiple procedures, discoloration and scarring are associated with donor site wounds. While skin grafting is commonly associated with burn treatment, in 2017, approximately 80% of acute wounds that required skin grafting were non-burn related injuries accounting for more than 200,000 procedures in the U.S.i
AVITA Medical is currently completing a pivotal trial for the use of the RECELL System for soft tissue reconstruction. Currently, the RECELL System is indicated in the U.S. for treatment of acute thermal burns. The clinical trial will compare the clinical performance of conventional autografting to that of widely meshed autografting with the RECELL System on acute non-burn full-thickness skin defects, with the goal of demonstrating that less donor skin is needed without compromising healing outcomes. Topline data from the trial will be shared later this year.
AVITA Medical has had a long-term positive relationship with BARDA since September 2015 and was of fundamental importance to the Company being able to achieve premarket approval for the RECELL System in late 2018.
This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201500028C
ABOUT AVITA MEDICAL, INC.
AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medical’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. The medical devices work by preparing a RES® REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patient’s skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.
AVITA Medical’s first U.S. product, the RECELL® System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018 and a new ease-of-use design was approved in 2022. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin™ Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL® Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.
In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit www.avitamedical.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the company’s control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.
This press release was authorized by the review committee of AVITA Medical, Inc.
right you are frobinso and the more painful for them the bigger spike up for us ... ;) ... as they say, "let her rip tater chip " !!!
Just released on youtube ... POET Technologies Discusses Its Product Roadmap and Reflects on Recent Successes
This is evidently where that quote originated from Lisa Thompson in this Zacks article :
https://scr.zacks.com/news/news-details/2021/POETF-POET-Plans-to-Compete-with-a-Superior-Offering-in-the-Medtech-Wearables-Market/default.aspx" rel="nofollow" target="_blank" >https://scr.zacks.com/news/news-details/2021/POETF-POET-Plans-to-Compete-with-a-Superior-Offering-in-the-Medtech-Wearables-Market/default.aspx[tag]insert-text-herehttps://scr.zacks.com/news/news-details/2021/POETF-POET-Plans-to-Compete-with-a-Superior-Offering-in-the-Medtech-Wearables-Market/default.aspx/tag]
Re-post from Reddit's POET board ...
Posted byu/Beginning_Cause_8487
2 days ago
Helpful
Keep your shares tight
Discussion
We were told we would have an uplisting from a position of strength. I really believe we do. So I wanted to give my opinion on a couple things.
ORDERS
I know orders are absolutely necessary, sometime. But take it easy. Institutions/funds aren't in a hurry. They don't have to rush anything. Besides many companies haven't reported orders or even customers and yet they are +- 10% in hands of institutions (RKLY, LWLG,...). So, just wait and keep your shares tight.
INSTITUTIONS
When they come, they want cheap shares. Usually shareprice gets driven down so they can buy in cheap. And they also don't get in on the first days post-listing. Given our small float, a 10% holding would imply 3,7M shares. Now, that's quite interesting, so keep your shares tight.
MEDIA
We get a lot of very exciting news interviews, announcements, SEC fillings, hints and quotes, but you have to listen to it. POET mgmt does this significantly more often than many other companies. This company has proven that it is very thoughtful, communicative and tactful. You don't want this company to rush things and make mistakes or give wrong signals to investors/competitors. So, keep your shares tight. Some examples of the last few months:
"The OFC event provided the Company with the opportunity to engage with several industry analysts, commentators, sell-side analysts and investment bankers."
"Exceeded what I would have expected going into OFC"
"Overall, the exhibition was an overwhelmingly successful event for POET."
"The POET exhibit had a continuous stream of attendees, including industry leaders, analysts and media."
"Early in 2022, the National University of Singapore and POET will launch a state-of-the-art hybrid optoelectronics integration assembly center that will work on products not directly related to the Super Photonics joint venture."
"The OFC event provided the Company with the opportunity to engage with several industry analysts, commentators, sell-side analysts and investment bankers."
"The Optical Interposer is an integration platform that is agnostic to the material system that any given device is built from, meaning that we can select the ‘best of breed' for the specific application rather than trying to do everything in silicon or any other material. This distinctive feature of the POET Optical Interposer technology, among others, means that we can address applications where conventional free-space optics or traditional silicon photonics cannot. We believe that POET represents the future of photonics integration."
"I had 3 objectives going into #OFC22 and they were all exceeded.”
"We had 40-50 meetings overall and are rapidly gaining traction with potential customers, including data center operators, networking systems and AI vendors and module companies," said Vivek Rajgarhia, President of POET Technologies. "Some of the more interesting partnering opportunities were with innovative device companies, looking to utilize POET's platform for the next generation of optical engines for transceivers and co-packaging applications."
"Optical engines deliver superior performance at industry leading cost, form factor and scale with wafer scale passive assembly"
"The Optical Interposer unlocks the packaging bottleneck in photonics"
"The Optical Interposer is THE ONLY chip scale integrated solution for modulated lasers (DML, EML) extending the applicability of these devices into the Tb era"
“So why invest in POET now? First of all, we have a technology that has been proven out by leading companies. We have a first-rate management team, with public company track records. We have a totally disruptive technology applied to large and known markets with huge potential. We are now commercializing after 4+ years of development. We’re not very well known outside of Canada—in fact, we’re probably not that well known inside of Canada—so because we trade only on the OTC in the US, we haven’t been able to attract as many investors as we would like to. Although we are not known, we will be soon. We have a solid, large company partner in China with investment in the JV with SANAN. The plans for the JV are to grow it, and to eventually possibly to take it public on the Star Board in a few years. And we’re expecting soon to be on the NASDAQ, which in my opinion, itself, will increase our share price because of the larger investment audience we’ll attract."
"Shareholders are now in a better position today than they ever were and they may not even know that."
"Ai is just a very exciting business for POET, just because of the volumes involved".
“Any time you are past the technology phase and getting into business development, getting into commercialization, starting to get into customers, becoming their preferred supplier, it’s always an exciting time… it’s also an extremely busy time for the company and there’s obviously a lot of things you’ve got to do. Sometimes we feel like we’re building the plane as it’s taking off, but that’s kind of what we do… As an investor base, I think you guys should take a closer look at us because we are definitely at an inflection point NOW”
"As photonics plays a larger role in our lives, the excitement around the industry builds. In 2022, it should have an unprecedented commercial impact, signaling even greater growth in the years ahead."
“The customized Optical Interposer platform that we have co-developed with POET is among the most advanced of its kind in high-speed computing.”
"So many ideas in the pipeline to develop" and shareholders are in the "best position they ever were and they might now even know that yet."
"The interposer is such a low loss medium and when I say low loss, not just low optical loss but low RF lost right. Low electrical loss that you know we're able to operate these products at approximately 30% lower power consumption of what might conventionally be achievable or possible."
"A lot of people attempting to flip-chip lasers, but we are the only ones in the world that have been successfully able to do it with extremely small directly modulated lasers (DML)"
"We believe that by having a platform that enables the use of these types of ultra small, ultra low power devices allows us to not only provide competitive solutions at 100G and 200G, but we can extend these solutions using DML lasers all the way to 1.6T/sec or even 2T/sec, which without our platform is simply not conceivable. We have the extension of a an otherwise ending roadmap."
"LR4 is a blue ocean."
"We just keep building momentum."
"POET's Optical Engine is 1/4 the size of a conventional chip-on-board DML solution."
"We're not the only ones referring to POET's technology as being 'amazing.'"
"Live demos of POET’s 200G FR4 TX engine & 400G FR4 RX engine were exceedingly well received by the dozens of attendees who viewed at our booth. The “semiconductorization” of photonics is truly a game-changer for the industry."
“We take data transmission to the next level.”
“Lithium niobate modulators have been used for the last 35 years, and have the best performance and reliability of any other modulator technology.”
"Truly Amazed" is how Raju Kankipati, POET Technologies' latest hire, felt when he first saw the company's Optical Interposer in action."
"A 400G DML-enabled product ... would act like a slingshot and propel innovation in a number of sectors."
"Samples are in the hands of multiple potential customers and partners and the early feedback is strongly positive."
"POET Technologies has an immense amount of intellectual talent for a company of its size. Led by CEO Dr. Suresh Venkatesan."
"POET’s Optical Interposer provides greater than 100 times more scalability than other options in the photonics industry. That’s because of the OI’s lower bill of materials and ease of integration."
“We are working closely with customers on further product customization for their specific end market applications & with others on proposals to leverage the benefits of our Optical Interposer platform.”
"We have a design win & PO with a large network systems company for our 100G CWDM4 and 100G LR4 optical engines. Our excellent performance and small form factor make us hard to beat!"
"Hybrid integration is on track to impact the industry in notable ways in 2022. Until we get there, companies ensnared in the supply-chain backlog can implement some sensible measures to mitigate the delays. One of the first things that can be done is to procure qualified secondary vendors who can help fill the gap when your primary supplier is unable to deliver. That is a step we took at POET Technologies in the spring and it has helped us limit the delays toward the commercialization of our products."
"Because we have been well-prepared for such a contingency, we do not believe this temporary lockdown will have any effect on our planned delivery schedule to customers, prospective customers or business partners.”
..............
CATALYSTS
Never forget our roadmap (-2028). We've now a senior level production line manager. So keep your shares tight.
FINANCIALS
We shouldn't be worried about the cash available and our burn-rate. That's been said many times. Maybe we'll need more money to develop our photospectrometer, but I'm sure POET will figure something out when signing that JV. Remember, production starts in 2H this year. We should see our first millions $$$ come in. So keep your shares tight.
FLOAT
The lower the liquidity (the more shares are registered to individuals), the higher the typical volatility, and that is true for both directions, including upside. So keep your shares tight.
MARKET
Everyone knows we're in a bear market . We have still Covid-19 outbreaks in China after a 2 year pandemic, a worldwide green transition and a Russia-Ukraine war. This all feeds inflation, which is already on a 40-year high. Then we have the hawkish Fed (beginning rate hikes). Retail investors need their money more then ever. Most people do not even have money left to invest. The market will need some time to heal. So keep your shares tight.
TAKE HOME MESSAGE
As Suresh stated, innovation is incremental. It takes some time, especially in these market conditions. In my opinion, behave as a longterm investor and sit this out. Enjoy the news we get and always keep your focus on the >1B revenue by 2028. A man once said: "If you are not willing to own a stock for 10 years, do not even think about owning it for 10 minutes.". So if you are stable enough to hold that long, you could become a very rich MF. Never forget the value of what you're holding.
GLTA
proto ... you are the first one to comment on this and is exactly why I re-posted it from the other site. Other than this comment, I have not found any "background" on this being a reality yet. I have continued to search various sites and have nothing to back it up yet. If I find I will certainly post it and if you come up with anything definitive I hope you will post it as well.
THANKS for responding,
John
exactly mister ... looks like a whole lot of us ended up here which has been very profitable ... ;) ... BTW, CHEERS to you !!!
loop ... it is FANTASTIC to see you my friend. Please let us hear more from you.
GOD Bless buddy,
John
couldn't pry me away with a knife ... too many possibilities for greatness here ... ;)
... for all of us ex-IDCC'ers ... ;)
I absolutely agree ... both of them have unique offerings that can solve and deliver what other companies can not, let alone compete with. We will get our share of the pie with both innovators ... ;)
For POET Technologies, OFC 2022 Proves Momentous ...
Rkf302 ... please send me an e-mail to jgupton970@aol.com and I will respond.
THANKS,
John
A good reminder from CWDM4 on Stocktwits POET board:
"POET is in talks with large wearable and mobile phone manufacturers in China and Korea and is working with a Chinese company already active in the field to design a product. POET has demonstrated an ability to develop products rapidly and at much lower cost to its competitors (nearly $400 million and eight years of development by Rockley and only $50 million and four years for POET) due to the simplicity of design of the POET optical interposer. In fact, the largest wearables company is not Apple but Huamei (Amazfit), a Chinese company. POET expects to have deal announced in the first half of 2022 in this market, and would base a capital raise on funding a team in China to build a spectrometer. Rockley has based its product on expensive Silicon Photonics and LEDs that do not have enough wavelengths and thus data, but POET’s solution would be smaller, less expensive and based on lasers able to penetrate the skin and provide information on many more metrics."
GREAT NEWS ...
https://www.gophotonics.com/news/details/2900-poet-technologies-to-deliver-optical-interposer-based-multi-laser-integrated-els-modules-to-celestial-ai and yet it does not show up in the news area of IHUB.
Another reason to knock us down today before this hit the wires ...
POET Technologies to Deliver Optical Interposer-Based Multi-Laser Integrated ELS Modules to Celestial AI
Posted Mar 15, 2022 by GoPhotonics Editorial Team
POET Technologies, the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and telecommunication markets, reported that it has entered into an agreement with Celestial AI to provide multi-laser integrated external light source (ELS) modules using its advanced packaging platform based on the POET Optical Interposer. The agreement includes a contract for continued platform development, along with a purchase order for initial quantities of the advanced modules.
Celestial AI is an Artificial Intelligence accelerator company that has a proprietary technology platform that enables the next generation of high-performance computing solutions. Celestial AI’s mission is to fundamentally transform computing efficiency with their Photonic Fabric™ technology platform, which uses light for data movement both within chips and between chips. “The customized Optical Interposer platform that we have co-developed with POET is among the most advanced of its kind in high-speed computing,” said David Lazovsky, founder and CEO of Celestial AI. “POET’s Light Engines provide us with precision optical power sources in a highly integrated form factor that meet the requirements for our Orion AI accelerator products.” Celestial AI’s Orion AI accelerator products serve the AI chipset market that is projected by Omdia to exceed $70 billion in 2025.
“We are truly excited to take the next step with Celestial AI, one of the leading technology companies in this burgeoning field, to create a highly differentiated means to co-package electronics and photonics and help overcome the fundamental challenges of speed and power faced in high-performance computing,” said Dr. Suresh Venkatesan, Chairman, and CEO of POET Technologies. “The challenges in this application are precisely those that the POET Optical Interposer was designed to overcome. They are the same as those faced by datacom and telecom companies as they seek to co-package electronics and optics and to achieve data transmission speeds of 3.2 and 6.4 Tbs across a number of channels with multiple wavelengths, with lower energy consumption and higher stability. The multi-laser integrated external light source developed for this application has direct applicability to other products in data communications and sensing.”